作者非常感谢斯洛文尼亚研究机构的国家预算和欧洲委员会的ESOPE项目（QLK - 2002 - 02003），根据第五框架计划资助的的财政支持。作者承认教授的贡献。马尔科Snoj，教授。玛雅Cemazar，Matej Merkac和雷达Likon此视频文章做准备。

电化学治疗过程由局部或全身药物注射交付应用到肿瘤的1电脉冲。关于治疗的详细信息公布在标准操作程序（SOP）2 。 治疗适应症： <ol><li>肿瘤类型：基底细胞癌和皮肤恶性黑色素瘤，乳腺癌，hypernephroma，卡波西氏肉瘤和其他转移。 </li><li>肿瘤的位置：访问的皮肤和身体的各个部位的皮下肿瘤结节。 </li><li>肿瘤的大小，可从3毫米，直径3-5厘米。 </li><li>结节数从1到100。 </li></ol>治疗过程： <ol><li>局部或全身麻醉，这取决于治疗结节的数目和位置。 </li><li>药物的选择：顺铂或博莱霉素。瘤内注入顺铂和博莱霉素，博莱霉素也静脉注射剂量在15000 IU / M 2。 intratumoural应用博莱霉素注射剂量为250-1000 IU /厘米3的肿瘤组织，顺铂0.5 -1毫克/厘米的肿瘤组织 3 </li><li>药品监督管理和应用的电脉冲之间的时间间隔;瘤内注射药物后，静脉给药后8分钟后立即。长达28分钟。 </li><li>电脉冲电化学发电机应提供从1 Hz到5 kHz的方波振幅1000伏以上，重复频率的电脉冲。 </li><li>电脉冲参数：如1000伏的脉冲，在两个电极板之间，频率为1 Hz或5千赫，脉冲持续时间100微秒的8毫米的距离。 </li><li>如果整个肿瘤不能包含两个电极之间的电脉冲应用程序应反复多次，以覆盖整个肿瘤区，包括安全边际。 </li><li>电极类型：小，浅表肿瘤结节电极板，电极针治疗更深种子结节在皮肤下。 </li></ol>治疗的其他特点： <ol><li>通常单一的治疗方法是有效地消除肿瘤结节;然而，电化学可以在剩下的肿瘤组织或其他肿瘤结节4周的时间间隔反复。 </li></ol>由于缺乏全身毒性 - 博莱霉素或顺铂剂量很低，因为需要 - 患者可以治疗门诊的基础上，可以离开医院治疗后很快。

<ol>
	<li>Mir, L. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Bases+and+rationale+of+the+electrochemotherapy.">Bases and rationale of the electrochemotherapy.</a> EJC Suppl. 4, 38-44 (2006).</li><li>Mir, L. M., Gehl, J., Sersa, G., Collins, C. G., Garbay, J. R., Billard, V., Geertsen, P., Rudolf, Z., O'Sullivan, G. C., Marty, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Standard+operating+procedures+of+the+electrochemotherapy:+instructions+for+the+use+of+bleomycin+or+cisplatin+administered+either+systemically+or+locally+and+electric+pulses+delivered+by+the+CliniporatorTM+by+means+of+invasive+or+non-invasive+electrodes.">Standard operating procedures of the electrochemotherapy: instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes.</a> EJC Suppl. 4, 14-25 (2006).</li><li>Okino, M., Mohri, H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Effects+of+high-voltage+electrical+impulse+and+an+anticancer+drug+on+in+vivo+growing+tumors.">Effects of high-voltage electrical impulse and an anticancer drug on in vivo growing tumors.</a> Jpn. J. Cancer Res. 78, 1319-1321 (1987).</li><li>Mir, L. M., Banoun, H., Paoletti, C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Introduction+of+definite+amounts+of+nonpermeant+molecules+into+living+cells+after+electropermeabilization:+direct+access+to+the+cytosol.">Introduction of definite amounts of nonpermeant molecules into living cells after electropermeabilization: direct access to the cytosol.</a> Exp. Cell Res. 175, 15-25 (1988).</li><li>Sersa, G., Cemazar, M., Miklavcic, D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Antitumor+effectiveness+of+electrochemotherapy+with+cis-diamminedichloroplatinum(II)+in+mice.">Antitumor effectiveness of electrochemotherapy with cis-diamminedichloroplatinum(II) in mice.</a> Cancer Res. 55, 3450-3455 (1995).</li><li>Sersa, G., Cemazar, M., Miklavcic, D., Rudolf, Z. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Electrochemotherapy+of+tumours.">Electrochemotherapy of tumours.</a> Radiol. Oncol. 40, 163-174 (2006).</li><li>Miklavcic, D., Beravs, K., Semrov, D., Cemazar, M., Demsar, F., Sersa, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+importance+of+electric+field+distribution+for+effective+in+vivo+electroporation+of+tissues.">The importance of electric field distribution for effective in vivo electroporation of tissues.</a> Biophys. J. 74, 2152-2158 (1998).</li><li>Miklavcic, D., Corovic, S., Pucihar, G., Pavselj, N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Importance+of+tumour+coverage+by+sufficiently+high+local+electric+field+for+effective+electrochemotherapy.">Importance of tumour coverage by sufficiently high local electric field for effective electrochemotherapy.</a> EJC Suppl. 4, 45-51 (2006).</li><li>Sersa, G., Jarm, T., Kotnik, T., Coer, A., Podkrajsek, M., Sentjurc, M., Miklavcic, D., Kadivec, M., Kranjc, S., Secerov, A., Cemazar, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Vascular+disrupting+action+of+electroporation+and+electrochemotherapy+with+bleomycin+in+murine+sarcoma.">Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma.</a> Brit. J. Cancer. 98, 388-398 (2008).</li><li>Mir, L. M., Belehradek, M., Domenge, C., Orlowski, S., Poddevin, B., Belehradek, J., Schwaab, G., Luboinski, B., Paoletti, C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Electrochemotherapy,+a+new+antitumor+treatment:+first+clinical+trial.">Electrochemotherapy, a new antitumor treatment: first clinical trial.</a> C. R. Acad. Sci. III. 313, (1991).</li><li>Mir, L. M., Glass, L. F., Sersa, G., Teissie, J., Domenge, C., Miklavcic, D., Jaroszeski, M. J., Orlowski, S., Reintgen, D. S., Rudolf, Z., Belehradek, M., Gilbert, R., Rols, M. P., Belehradek, J., Bachaud, J. M., DeConti, R., Stabuc, B., Cemazar, M., Coninx, P., Heller, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Effective+treatment+of+cutaneous+and+subcutaneous+malignant+tumours+by+electrochemotherapy.">Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy.</a> Brit. J. Cancer. 77, 2336-2342 (1998).</li><li>Gothelf, A., Mir, L. M., Gehl, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Electrochemotherapy:+results+of+cancer+treatment+using+enhanced+delivery+of+bleomycin+by+electroporation.">Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation.</a> Cancer Treat. Rev. 29, 371-387 (2003).</li><li>Byrne, C. M., Thompson, J. F., Johnston, H., Hersey, P., Quinn, M. J., Hughes, M., McCarthy, W. H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Treatment+of+metastatic+melanoma+using+electroporation+therapy+with+bleomycin+(electrochemotherapy).">Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy).</a> Melanoma Res. 15, 45-51 (2005).</li><li>Sersa, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+state-of-the-art+of+electrochemotherapy+before+the+ESOPE+study:+advantages+and+clinical+uses.">The state-of-the-art of electrochemotherapy before the ESOPE study: advantages and clinical uses.</a> EJC Suppl. 4, 52-59 (2006).</li><li>Sersa, G., Miklavcic, D., Cemazar, M., Rudolf, Z., Pucihar, G., Snoj, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Electrochemotherapy+in+treatment+of+tumours.">Electrochemotherapy in treatment of tumours.</a> EJSO. 34, 232-240 (2008).</li><li>Marty, M., Sersa, G., Garbay, J. R., Gehl, J., Collins, C. G., Snoj, M., Billard, V., Geertsen, P. F., Larkin, J. O., Miklavcic, D., Pavlovic, I., Paulin-Kosir, S. M., Cemazar, M., Morsli, N., Soden, D. M., Rudolf, Z., Robert, C., O'Sullivan, G. C., Mir, L. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Electrochemotherapy+-+an+easy,+highly+effective+and+safe+treatment+of+cutaneous+and+subcutaneous+metastases:+results+of+ESOPE+(European+Standard+Operating+Procedures+of+Electrochemotherapy)+study.">Electrochemotherapy - an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study.</a> EJC Suppl. 4, 3-13 (2006).</li><li>Quaglino, P., Mortera, C., Osella-Abate, S., Barberis, M., Illengo, M., Rissone, M., Savoia, P., Bernengo, M. G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Electrochemotherapy+with+intravenous+bleomycin+in+the+local+treatment+of+skin+melanoma+metastases.">Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases.</a> Ann. Surg. Oncol. 15, 2215-2222 (2008).</li></ol>

最初是由冲之M和和平号空间站的LM 3,4 electroporative电脉冲的细胞暴露在博莱霉素的细胞毒性增加。此后电化学被证明是有效的顺铂5。在接下来的几年广泛的临床前数据收集在体外和体内肿瘤模型。治疗效果取决于药物剂量，其管理的途径，药物注射和电脉冲的应用程序的时间，电场强度，具有足够高的电场（E）的覆盖面，并选择适当的电极和定位方面肿瘤1,6,7,8。此外，内在机制的电化学的有效性进行了详细阐述，这表明，除了直接影响到肿瘤细胞，血管破坏作用和免疫反应的电化学涉及 1,6,9 。所有这些收集的数据使电化学翻译成诊所。 第一临床试验表明，头部和颈部和黑色素瘤结节 10电化学成效。后来，其效益是其他类型的肿瘤，如皮肤基底细胞癌，黑色素瘤皮肤转移，乳腺肿瘤，hypernephroma和卡波济氏肉瘤，证明。有评估集体所有临床数据上的电化学与博莱霉素，顺铂11-15出版的几份报告。总体而言，治疗肿瘤的反应率约80％的客观反应和大约70％ 的 15,16完整的答复。有效性，可重复治疗17甚至更高。 所有这些临床数据已启用电化学在欧洲一些国家采用作为标准治疗，治标不治本的意图，对各种肿瘤。这种治疗方法的未来，是引入内部的肿瘤和转移，处理和电化学综合治疗，基因治疗或放射治疗。这些尝试已经在进行之中。

<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">	
		
		<div>
		<table border="1">
		<thead>
		<tr>
		<th>Material Name</th>
		<th>Type</th>
		<th>Company</th>
		<th>Catalogue Number</th>
		<th>Comment</th>
		</tr>
		</thead>
		<tbody>
		
<tr>
<td>Bleomycin (Blenamax)</td>
<td>Reagent</td>
<td>Pharmachemie B.V.</td>
<td>&nbsp;</td>
<td>chemotherapeutic drug used in electrochemotherapy </td>
</tr>
<tr>
<td>Cliniporator</td>
<td>Other</td>
<td>IGEA srl</td>
<td>&nbsp;</td>
<td>Generator of electric pulses</td>
</tr>		</tbody>
		</table>
		</div>

electrochemotherapy of tumours

电化学是一个结合使用某些化疗药物应用于治疗肿瘤结节的电脉冲。当地的电脉冲肿瘤中的应用，增加进入细胞的药物输送，特别是在电脉冲应用的网站。只有那些其运输通过质膜是阻碍化疗药物增加药物的吸收是电脉冲交付。其中许多药物，至今已经过测试，博莱霉素，顺铂发现从临床前试验，临床使用的方式。在临床研究中收集的临床数据表明，约80％的治疗不同恶性肿瘤的皮肤和皮下肿瘤结节在客观反应，从这些，大约有70％完全缓解后的电化学单一的应用程序。通常只有一个治疗是必要的，然而，电化学，可反复几次具有同等效力每次每隔几个星期。在一个有效的根除治疗结节的治疗效果，具有良好的无组织疤痕的美容效果。

Watch this Scientific Journal Video about Electrochemotherapy of Tumours at JoVE.com

Electrochemotherapy of Tumours

电化学是如某些化疗药物顺铂和博莱霉素应用于治疗肿瘤结节的电脉冲的联合使用。我们目前对皮下黑色素瘤皮肤转移treatmen电化学临床协议。

电化学的肿瘤

Electrochemotherapy is a combined use of certain chemotherapeutic drugs and electric pulses applied to the treated tumour nodule. Local application of ...

Research

JoVE Journal

Biology

24.3K 次观看.  Institute of Oncology Ljubljana. 电化学是如某些化疗药物顺铂和博莱霉素应用于治疗肿瘤结节的电脉冲的联合使用。我们目前对皮下黑色素瘤皮肤转移treatmen电化学临床协议。